<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579718</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1062</org_study_id>
    <nct_id>NCT04579718</nct_id>
  </id_info>
  <brief_title>A Study of Radiotherapy Planning System Software ---- Zeus Cloud</brief_title>
  <official_title>A Multicenter Study on the Feasibility of a Radiotherapy Treatment Planning System (TPS) Software---Zeus Cloud</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affilicated Suzhou Science and Technology Town Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility of Zeus Cloud TPS in the design of photon intensity modulated&#xD;
      radiation therapy (IMRT) plan for tumors in various parts of the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a self-control, multi-center non-inferiority study. Subjects meeting inclusion&#xD;
      criteria have radiation treatment plans designed by Zeus Cloud TPS and Eclipse treatment&#xD;
      planning software from Varian, respectively. The qualities of two plans are compared.&#xD;
&#xD;
      This is a observational study as the two plans are not executed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The qualification rate of treatment plans based on dosimetry</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The conformability index of radiation dose to the target</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>single-field pass rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite-field pass rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Eclipse</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Zeus Cloud TPS V1.0</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zeus Cloud TPS V1.0</intervention_name>
    <description>Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.</description>
    <arm_group_label>Zeus Cloud TPS V1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eclipse</intervention_name>
    <description>Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.</description>
    <arm_group_label>Eclipse</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed brain glioma, nasopharyngeal carcinoma, lung cancer, esophageal&#xD;
        cancer, gastric cancer, liver cancer, prostate cancer, cervical cancer and rectal cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with confirmed brain glioma, nasopharyngeal carcinoma, lung cancer,&#xD;
             esophageal cancer, gastric cancer, liver cancer, prostate cancer, cervical cancer and&#xD;
             rectal cancer;&#xD;
&#xD;
          2. The medical imaging data (CT) of the subjects were complete and available;&#xD;
&#xD;
          3. Between 18 and 75 years old, regardless of gender;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patients had metal implants;&#xD;
&#xD;
          2. Not suitable for clinical trials judged by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, MD</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Treatment Planning System</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

